Applications of porcine reproductive and respiratory syndrome virus (PRRSV), mycoplasma hyopneumoniae and PCV-2 antigen in preparation of vaccine

A technology of mycoplasma hyopneumoniae and PCV-2, applied in bacterial antigenic components, viral antigenic components, antibacterial drugs, etc., can solve problems such as delaying PRRSV vaccine immunization time, reducing pig herd tolerance to PRRSV, prolonging piglet immunization time of PRRSV vaccine, etc.

Inactive Publication Date: 2014-09-17
PU LIKE BIO ENG
View PDF6 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0017] The application immunized piglets twice with the Mycoplasma hyopneumoniae single vaccine and the combined vaccine containing the Mycoplasma hyopneumoniae component. Although the so-called "attenuated PRRSV strain vaccine's impact on the immune effect of Mycoplasma hyopneumoniae was avoided, the application of the PRRSV vaccine was postponed." The immunization time is 7 to 35 days, which will inevitably prolong the time for piglets to be immunized with PRRSV vaccine and reduce the ability of pigs to tolerate PRRSV

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Applications of porcine reproductive and respiratory syndrome virus (PRRSV), mycoplasma hyopneumoniae and PCV-2 antigen in preparation of vaccine
  • Applications of porcine reproductive and respiratory syndrome virus (PRRSV), mycoplasma hyopneumoniae and PCV-2 antigen in preparation of vaccine
  • Applications of porcine reproductive and respiratory syndrome virus (PRRSV), mycoplasma hyopneumoniae and PCV-2 antigen in preparation of vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Embodiment 1, the preparation of porcine circovirus type 2, PRRSV, mycoplasma hyopneumoniae combination vaccine

[0035] 1. Antigen Preparation

[0036] 1.1 Preparation of porcine circovirus type 2 antigen

[0037] (1) Passaging and culturing of cells for seedling production: PK15 cells were taken, digested and passaged by EDTA-trypsin cell dispersion solution (Hank's solution containing 0.25 trypsin (1:250), 0.02% EDTA), to obtain 90% MEM solution, 10% bovine serum, each 100 units / ml of penicillin sodium and streptomycin sulfate, the cell growth medium adjusted to pH 7.2 to continue culture, culture temperature is 37 ℃, when a good cell monolayer is formed, it is used for continued passage Or inoculated in a bioreactor for microcarrier suspension culture, wherein the bioreactor is a bioreactor that can automatically control parameters such as temperature, pH, dissolved oxygen, and stirring speed, and is suitable for microcarrier suspension culture.

[0038] (2) Propa...

Embodiment 2

[0058] Embodiment 2, PCV-2, PRRSV, mycoplasma hyopneumoniae combination vaccine application

[0059] Use the self-made component I and component II in Example 1 of the present invention in combination, and use component I as the diluent to dilute component II to form a joint vaccine to prevent the three diseases of Mycoplasma hyopneumoniae, PCV-2 and PRRSV. The immunization procedure is as follows: Firstly, 7-day-old piglets are immunized with component I diluted with component II for the first vaccination, and 21 days later, component I is used for the second immunization. At the same time of immunization, the control group was immunized with the corresponding single vaccine to evaluate the difference in immune effect between the combined application of the three antigen components and the single use of the corresponding single antigen.

[0060] 1. Materials

[0061] PCV-2 and Mycoplasma hyopneumoniae dual vaccine, ie component I, was prepared and tested according to Example...

Embodiment 3

[0092] Example 3, Application of PCV-2 Antigen, Mycoplasma Hyopneumoniae Antigen and PRRSV Attenuated Strain Combination Vaccine in Pigs Infected with Mycoplasma Hyopneumoniae

[0093] 1. Test method

[0094] 1.1 Research purpose and experimental design

[0095] In Example 2, the test animals selected for the evaluation of the immune effect of the multi-component vaccine and the single vaccine were antigen-antibody double-negative piglets, but Mycoplasma hyopneumoniae widely exists in pig herds in actual clinical practice. Therefore, this embodiment aims at immunizing porcine PCV-2, PRRSV and Mycoplasma hyopneumoniae in pig herds with Mycoplasma hyopneumoniae in order to evaluate the immune effect. This example included piglets from 3 scale farms with M. hyopneumoniae, each farm containing about 200 piglets. The piglets in each pig farm were divided into two groups: the first group of 7-day-old piglets were intramuscularly injected with the triple vaccine consisting of compo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides applications of porcine reproductive and respiratory syndrome virus (PRRSV) antigen in immune dose, a mycoplasma hyopneumoniae antigen in immune dose and a PCV-2 antigen in immune dose in preparation of a vaccine which is used for preventing and treating pigs being polluted by mycoplasma hyopneumoniae or pigs being threatened by the mycoplasma hyopneumoniae. On the premise of not influencing an immune effect on the mycoplasma hyopneumoniae, the applications, aiming at pigs being polluted by mycoplasma hyopneumoniae or pigs being threatened by the mycoplasma hyopneumoniae, can enable immune time of the PCV-2 and the PRRSV to be brought forward and can control the three diseases: the mycoplasma hyopneumoniae, the PPRSV and the PCV-2 at the same time.

Description

technical field [0001] The invention relates to the application of porcine PRRSV, mycoplasma hyopneumoniae and PVC-2 antigen in vaccine preparation. Background technique [0002] Porcine circovirus disease is a multisystem dysfunction disease of pigs caused by porcine circovirus (PCV). Porcine circovirus belongs to the family Circoviridae and is one of the smallest animal viruses ever discovered. According to the pathogenicity and genome difference of porcine circovirus, it can be divided into non-pathogenic (or PK15-derived) porcine circovirus type 1 (PCV-1) and pathogenic (PMWS-derived) Porcine circovirus type II (PCV-2). Since the serological evidence of PCV2 infection in pigs was reported in my country in 2000, various regions have reported one after another, and the epidemic range has spread to the whole country. The average positive rate of pigs is 38.47%, and the positive rate of pig farms is more than 58.75%. In response to this problem, there are commercialized i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/295A61K39/12A61K39/02A61P31/04A61P31/14A61P31/20
Inventor 张许科孙进忠白朝勇
Owner PU LIKE BIO ENG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap